• Lisata Therapeutics and GATC Health launch strategic collaboration utilizing GATC's AI-powered Multiomics Advanced Technology platform to optimize drug development and improve success rates.
• GATC's AI platform will analyze Lisata's investigational drug certepetide to identify optimal development pathways for metastatic pancreatic cancer and potential new indications.
• The partnership aims to significantly reduce traditional drug development risks and costs while accelerating the path to market through AI-driven analysis and targeted clinical trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.